Tazbentetol - Spinogenix
Alternative Names: SPG-302; Tazbentetol-SpinogenixLatest Information Update: 09 Apr 2026
At a glance
- Originator Spinogenix
- Class Antidementias; Antiglaucomas; Antineoplastics; Antipsychotics; Benzene derivatives; Benzothiazoles; Ethylene glycols; Neuroprotectants; Small molecules
- Mechanism of Action Synaptic transmission modulators
-
Orphan Drug Status
Yes - Amyotrophic lateral sclerosis
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Alzheimer's disease; Amyotrophic lateral sclerosis; Schizophrenia
- Preclinical Glaucoma
Most Recent Events
- 26 Mar 2026 Efficacy pharmacodynamics and adverse events data from a phase II trial in Schizophrenia released by Spinogenix
- 11 Mar 2026 Spinogenix completes enrollment in phase-II clinical trials in Schizophrenia (In adults) in USA and Australia (PO) (NCT06442462)
- 08 Jan 2026 Spinogenix plans a phase II trial for Amyotrophic lateral sclerosis in March 2026 (PO) (NCT07325591)